Skip to main
ARDT

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Ardent Health Inc. exhibited strong financial performance with an EBITDA of $143 million, reflecting a significant year-over-year growth of 46% and an improved margin of 9.1%, up 240 basis points. The company reported a 2.9% increase in admissions, aligning with the high end of its annual guidance, indicating robust operational growth. Additionally, ongoing favorable trends in the hospital sector, along with opportunities for advancing its outpatient strategy, suggest that Ardent is well-positioned to enhance its earnings potential moving forward.

Bears say

The negative outlook on Ardent Health Inc. is primarily driven by a disappointing EBITDA performance, which, despite a year-over-year increase, fell 2% short of estimates due to an inflated third-quarter figure influenced by a pull forward of $15M-$20M from the subsequent quarter. Furthermore, the company is experiencing a significant revenue adjustment of $43M linked to its transition to the Kodiak revenue cycle management platform, casting doubt on accounts receivable collectability and leading to reduced growth expectations. As a result, financial projections for 2025 and 2026 have been substantially lowered, indicating a potential transition to minimal or negative EBITDA growth, reflected in a 9% cut to 2025 EBITDA guidance.

ARDT has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 12 analysts, ARDT has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.